Adults with dermatomyositis have spent decades taking medicines designed for other diseases. That changed on August 27 with the Food and Drug Administration's approval of Lisraya, known generically as brepocitinib, the first oral therapy and the first targeted therapy cleared specifically for the condition in adults.
Dermatomyositis is a rare systemic autoimmune disease in which the immune system attacks muscle and skin at the same time. Patients live with progressive muscle weakness alongside extensive skin lesions that are painful, itchy, and disfiguring, plus sensitivity to light and touch. The FDA granted the drug orphan drug designation, a status reserved for treatments of conditions affecting fewer than 200,000 Americans.
The practical burden the approval targets is steroids. Standard care has leaned on glucocorticoids, methotrexate and other drugs borrowed from adjacent conditions, and long-term high-dose steroid dependence carries its own costs in bone density, blood sugar, infection risk and appearance.
An Approval the Agency Framed as Overdue
The FDA was unusually direct about the gap this fills.
"Today's approval is a meaningful step forward," said Nikolay Nikolov, M.D., director of the Office of Immunology and Inflammation in the agency's Center for Drug Evaluation and Research, in the FDA announcement. He said patients had long faced an unmet need and often relied on therapies meant for other diseases.
Lisraya received orphan drug and priority review designations before the decision. Priority review is reserved for medicines that would offer significant improvements in safety or efficacy for a serious condition.
One precision point matters for accuracy. This is not the first approved treatment for adult dermatomyositis. Intravenous immunoglobulin was approved for the condition in 2021. Lisraya is the first oral option and the first targeted therapy, which is a meaningful distinction for patients weighing an infusion against a daily tablet.
The Trial Behind It and What It Measured
The approval rests on VALOR, which the developer describes as the largest dermatomyositis trial ever conducted.
VALOR was a Phase 3 randomized, double-blind, multicenter, placebo-controlled study that enrolled 241 adults. Participants were assigned to brepocitinib 30 mg, 15 mg, or placebo once daily for 52 weeks, across a wide range of background therapies including none at all. The primary endpoint was the Total Improvement Score at week 52, a composite built from six measures: muscle strength, physical function, skin and other disease activity, muscle enzymes, and physician and patient assessments of overall health.
Participants on the approved 30 mg dose had a higher average Total Improvement Score than those on placebo, with gains in physical function and skin disease activity and a greater likelihood of reducing corticosteroid use by week 48. The steroid-sparing numbers are the most concrete part of the result: 55 percent of patients on the drug achieved both moderate or better improvement and minimal or no steroid use by the end of the study, compared with 30 percent on placebo. Among those taking at least 7.5 mg per day of prednisone-equivalent steroids at baseline, 62 percent tapered to minimal or no steroid use versus 38 percent on placebo, and 45 percent came off steroids entirely versus 29 percent, according to the company's approval announcement.
Two limits belong up front. The trial ran 52 weeks, so durability beyond a year in the real world is not established. And 241 participants is large for dermatomyositis but small in absolute terms, which means rarer safety signals may only emerge with broader use. Primary results were published in the New England Journal of Medicine, with skin-specific secondary endpoints published later in JAMA Dermatology.
The Boxed Warning Belongs at the Front of the Conversation
Brepocitinib inhibits both Janus kinase 1 and tyrosine kinase 2, blocking inflammatory signaling upstream of the muscle and skin damage.
That mechanism comes with a boxed warning covering serious infections, increased all-cause mortality, malignancy, major adverse cardiovascular events, and thrombosis. Several of those warnings derive from findings with a different JAK inhibitor studied in rheumatoid arthritis patients aged 50 and older with a cardiovascular risk factor, and the label notes that Lisraya is not approved for rheumatoid arthritis. Current and former smokers carry additional risk for malignancy and cardiovascular events. The drug is also not recommended alongside other JAK inhibitors, other TYK2 inhibitors, or biologic disease-modifying antirheumatic drugs.
The relevant questions before a first prescription are concrete: infection history, including tuberculosis and shingles exposure; clotting history; cardiovascular risk factors; smoking history; cancer history; and what vaccinations should be brought up to date. Patients are tested for latent and active tuberculosis before and during treatment, and live vaccines need to be handled before immunosuppression begins.
Monitoring continues after the first prescription. The label flags neutropenia, lymphopenia, anemia, lipid increases, and liver enzyme elevations, along with a risk of hypoglycemia in patients with diabetes and gastrointestinal perforation. Patients are told to report fever, persistent cough, a spreading rash, or new leg swelling and shortness of breath rather than waiting for a scheduled visit. The most common adverse reactions in the trial were upper respiratory tract infection, headache, fatigue, urinary tract infection, and nausea. Discontinuation because of adverse reactions occurred in 6 percent of patients on the 30 mg dose, compared with 11 percent on placebo.
Nobody should stop steroids or another existing dermatomyositis therapy because of this approval. Steroid tapering is a supervised process, and abrupt discontinuation carries its own risks. This article is general information and is not medical advice.
Cost Support Exists, but the Price Does Not
Priovant, the Roivant subsidiary that holds the approval, says Lisraya is available immediately in the United States through a limited network of specialty pharmacies, and that eligible patients may pay as little as $0 per month through its patient support program.
Copay support programs typically exclude patients on Medicare and Medicaid, which is the group most likely to include the older adults dermatomyositis often affects. No list price has been published, and orphan-designated specialty drugs generally carry high list prices that determine what insurers require before approving a prescription. Patients should expect prior authorization and should ask the prescribing office who handles that paperwork.
The label itself is unusually broad for a rare disease drug, with no restrictions based on disease activity, clinical presentation, or prior treatment, and it can be used alone or added to existing therapy. That breadth removes one common access barrier but does not settle how payers will respond, as trade coverage of the approval has noted.
What remains unknown is how long the benefit holds, whether the drug reduces the long-term disability and lung complications that drive outcomes in this disease, and how payers will position it against immunoglobulin. Longer-term follow-up data and any guideline updates from rheumatology societies are the next things to watch. MedicalDaily will report pricing disclosures, coverage decisions, and extended VALOR results as they are published.
Key Questions Answered
What was approved? Lisraya, brepocitinib 30 mg, a once-daily oral tablet for adults with dermatomyositis.
Is it the first treatment for the disease? It is the first oral and first targeted therapy approved for it. Intravenous immunoglobulin was approved for adult dermatomyositis in 2021.
What is dermatomyositis? A rare autoimmune disease causing progressive muscle weakness and painful, itchy skin lesions, along with sensitivity to light and touch.
What did the trial show? In a 52-week study of 241 adults, the 30 mg dose improved a composite disease activity score more than placebo and helped patients reduce steroid use.
What are the safety considerations? A boxed warning covering serious infections, increased all-cause mortality, malignancy, major adverse cardiovascular events, and thrombosis.
Should patients stop their steroids? No. Tapering must be supervised by a clinician. Abrupt discontinuation carries its own risks.
What will it cost? No list price has been published. The manufacturer says eligible patients may pay as little as $0 per month through a support program.
